Adherium Ltd. · ASX:ADR
Adherium — Investor Presentation (August 2022)
18 slides from Adherium's investor presentation, August 2022
Slide 1: Leading respiratory eHealth
Leading respiratory eHealth August 2022
Slide 2: Disclaimer and Forward-Looking Statement
DISCLAIMER AND FORWARD-LOOKING STATEMENT The material contained herein is of a general nature & has only been These risks & uncertainties include, but are not limited to: prepared as a presentation aid. This presentation does NOT contain all of i. the possible delays in & the outcome of product deve
Slide 3: Adherium is improving health outcomes in chronic respiratory disease
Adherium is improving health outcomes in chronic respiratory disease through world- leading remote patient monitoring technology and data ©Adherium 2022
Slide 4: Executive Summary
EXECUTIVE SUMMARY UNMET NEED • COPD and Asthma large global market (25M Asthmatics & 26M COPD patients in the US alone); ongoing cost burden. • Compromised patient quality of life and safety with ~92% poor inhaler technique and low adherence. • Current medical focus on reactive treatment vs. prevent
Slide 5: Highly Experienced Leadership Team
HIGHLY EXPERIENCED LEADERSHIP TEAM Rick Legleiter Francis White Keven Gessner Geoff Feakes Tara Creaven-Capasso Rob T urnbull Chief Executive Officer Vice President, Global Executive VP – Advisor Chief Technology Officer Vice President, Quality, General Manager and Business Development Regulatory &
Slide 6: Our Solution – The Hailie Platform
HAILIE PORTAL & OUR SOLUTION – THE HAILIE PLATFORM HAILIE SENSOR SDK/API Captures data for patient Compatible today with 91% SETS A NEW STANDARD FOR PREVENTATIVE TREATMENT of the US top 20 inhaler management, digital WITH INTEGRATED DATA INSIGHTS ENABLING DOCTOR health records, clinical medication b
Slide 7: Go-to-Market: Building Repeatable and Scalable Business Across Multiple Channels
GO-TO-MARKET: BUILDING REPEATABLE AND SCALABLE BUSINESS ACROSS MULTIPLE CUSTOMER CHANNELS AND REVENUE MODELS FY23 FY24 FY25 FY26 Gather real-world Market validation with Major multiple Establish Software OBJECTIVE: outcome data with 80,000 patient objective partners on recurring as a Medical leading
Slide 8: Catalysts for Success
CATALYSTS FOR SUCCESS CORE PILLARS MILESTONES Superb end-to-end value proposition and experience for • Continue to map out and execute on patient and patients and their doctors managing Asthma and COPD doctor experience • Cash flow positive objective targeting 80,000 patients on platform in FY24 ~1%
Slide 9: Unmet Need: Significant Burden to Health Systems and Respiratory Patients
UNMET NEED: SIGNIFICANT BURDEN TO HEALTH SYSTEMS AND RESPIRATORY PATIENTS FROM PREVENTABLE GAPS IN INHALER TECHNIQUE AND ADHERENCE COPD THIRD UP TO 92% OF PREVENTABLE 80% OF LEADING CAUSE ASTHMA PATIENTS HOSPITALIZATION ASTHMA-RELATED OF DEATH USE THEIR COST US HEALTH HOSPITALIZATIONS GLOBALLY INHAL
Slide 10: Time is Now for Remote Patient Monitoring
TIME IS NOW FOR REMOTE PATIENT MONITORING: ADHERIUM PERFECTLY PLACED Financial incentives for doctors, hospital systems, medical groups • Private insurers and public payors realize savings with remote patient monitoring • Two new US reimbursement codes for doctors to get paid: • Remote Physiological
Slide 11: A Flexible Channel Partner Platform
A FLEXIBLE CHANNEL PARTNER PLATFORM PROFESSIONAL PORTALS PATIENT TOOLS Health Care Professional Hailie App Population Health CLINICAL Dashboard ECOSYSTEM Adherium Health Data Hailie Digital Device Family Electronic Health Record 3rd Party App RestAPI Patient Management with Hailie Software Developme
Slide 12: Revenue by Generating and Transmitting Patient Data and Insights
REVENUE BY GENERATING AND TRANSMITTING PATIENT DATA AND INSIGHTS DATA SET WHAT WE PROVIDE REVENUE TYPES US ASTHMA AND COPD PATIENTS 1 TOTAL ADDRESSABLE 51 M MARKET Medication adherence data sets = Remote inhaler use monitoring 1. SaaS and data fees 2. Per member/month (PMPM) fees 3. Increase + servi
Slide 13: Partner of Choice: An Accelerated Growth Strategy
PARTNER OF CHOICE: AN ACCELERATED GROWTH STRATEGY NOW: DELIVERING ON PRODUCT NEXT: FOCUS ON RECURRING REMOTE FUTURE: DEVELOP DATA INSIGHTS DEVELOPMENT MILESTONES PATIENT MONITORING REVENUE AND DATA SCIENCE PORTFOLIO Expand platform with new, next-generation Establish new commercial partnerships Acqu
Slide 14: Appendices
Appendices References and data links available upon request Confidential ©Adherium 2022 14
Slide 15: Board: Proven Commercial, Clinical and Technical Leadership
BOARD: PROVEN COMMERCIAL, CLINICAL AND TECHNICAL LEADERSHIP Lou Panaccio Jeremy Curnock Cook George Baran Bruce McHarrie William Hunter James Ward-Lilley Independent Independent Non-Executive Director Independent Independent Independent Non-Executive Chair Non-Executive Director Non-Executive Direct
Slide 16: Intellectual Property and Global Patent Protection
INTELLECTUAL PROPERTY AND GLOBAL PATENT PROTECTION Adherium’s Hailie technology has registered designs and patents worldwide. 73 registered designs 25 registered designs 4 granted utility patents 4 granted utility patents 180 4 registered designs US UK/EU China Japan 10 registered Patents & 8 grante
Slide 17: Extensive Hailie Technology Clinical Validation
EXTENSIVE HAILIE TECHNOLOGY CLINICAL VALIDATION Hailie technology has been referenced in more than 100 independent peer- reviewed publications involving over 13,000 patients. These publications include Hailie sensors Across have been validation six independent used in 42 studies, validation studies,
Slide 18: Hailie Sensor Portfolio with US FDA 510(k) Clearances
HAILIE SENSOR PORTFOLIO WITH US FDA 510(k) CLEARANCES New, next generation sensors with physiological data capability for Anoro® Ellipta® / Arnuity® Ellipta® / for Symbicort® HFA Breo® Ellipta® / for Bevespi Aerosphere® Incruse® Ellipta® / Trelegy ® Ellipta® for Ventolin® HFA for Advair® HFA for Flo